SEK 10 million extra to drug approvals

When the European Medicines Agency (EMA), which is headquartered in London, receives applications from drug makers seeking marketing approval for new treatments in Europe, it passes on the applications to national drug agencies.

Since the summer, and as a result of Brexit, the EMA has stopped all complicated drug approval processes in the UK. Instead a number of these applications are now being passed on to the Swedish Medical Products Agency which is to receive an extra SEK 10 million from the government so that it can recruit a number of experts.